Spyre Therapeutics
Jeff Albers has extensive leadership experience in the biotechnology sector, serving as the Chairman and former Chief Executive Officer of Blueprint Medicines from 2014 to 2022. Albers is a Venture Partner at Atlas Venture and holds board member positions at Kymera Therapeutics and Spyre Therapeutics. Previously, Albers was the President for the US at Algeta ASA. Academic credentials include a law degree from Georgetown University Law Center and an MBA from Georgetown University McDonough School of Business.
This person is not in the org chart
This person is not in any teams
Spyre Therapeutics
Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.